Tumour Response to Cabozantinib in a Transgenic Mouse Model of Neuroblastoma Assessed by Multiparametric MRI
Gilberto S. Almeida 1 , Philippa King 2 , Yann Jamin 1 , Albert Hallsworth 2 , Hannah Webber 2 , Sergey Popov 3 , Louis Chesler 2 , and Simon P. Robinson 1
Radiotherapy and Imaging, The Institute of
Cancer Research, Sutton, Surrey, United Kingdom,
Studies, The Institute of Cancer Research, Sutton,
Surrey, United Kingdom,
Pathology, The Institute of Cancer Research, Sutton,
Surrey, United Kingdom
Both Vascular Endothelial Growth Factor (VEGF) and the
Hepatocyte Growth Factor (HGF)/c-MET signalling pathway
are implicated in the progression of human neuroblastoma.
In this study we demonstrate the efficacy of
cabozantinib, a small-molecule kinase inhibitor active
against both VEGFR2 and MET and currently in clinical
trials against neuroblastoma, in the Th-MYCN genetically
engineered mouse model of neuroblastoma and established
both native spin lattice relaxation time T1 and
transverse relaxation rate R2* as early non-invasive
biomarkers of response, which were associated with
significant increase in necrosis, and significant
decrease in microvessel density.
This abstract and the presentation materials are available to members only;
a login is required.